Devax, Inc. Receives CE Mark for the AXXESS Drug Eluting Bifurcation Stent
7/29/2010 6:52:54 AM
More...
|
Medical Device Company Devax, Inc. Withdraws IPO Plans
12/14/2007 12:14:36 AM
More...
|
Devax, Inc. Announces Completion of Enrollment of DIVERGE Trial of Novel Drug
12/12/2007 9:34:31 AM
More...
|
Devax, Inc. Files for $85 Million IPO
5/4/2007 9:26:21 AM
More...
|
Devax, Inc. Initiates Enrollment In The DIVERGE Clinical Trial With The AXXESS(TM) Drug Eluting Bifurcation Stent System
6/21/2006 2:33:01 PM
More...
|
Devax, Inc. Closes On $32 Million Of Series D Financing
11/2/2005 1:31:32 PM
More...
|
Devax, Inc. Completes Enrollment In The First Drug Eluting Stent Clinical Trial For A Dedicated Bifurcated Coronary Stent System
10/19/2005 5:12:04 PM
More...
|
Devax, Inc. Receives CE Mark For The AXXESS Bifurcated Stent System
10/19/2005 5:09:42 PM
More...
|
Devax, Inc. Licenses Coating And Drug-Eluting Technology For Its Axxess Bifurcated Stent Platform From Occam International B.V., An Affiliate Of Biosensors International
10/19/2005 5:09:38 PM
More...
|
Devax, Inc. Initiates First Drug-Coated Stent Clinical Trial For A Dedicated Bifurcated Coronary Stent System
10/19/2005 5:08:51 PM
More...
|